| scholarly article | Q13442814 |
| P50 | author | Simon Lovestone | Q30582986 |
| Madhav Thambisetty | Q71775824 | ||
| P2093 | author name string | Abdul Hye | |
| Alison L Baird | |||
| Sarah Westwood | |||
| Liu Shi | |||
| Richard Dobson | |||
| P2860 | cites work | Alzheimer disease: Sex-specific inflammatory link to early Alzheimer pathology | Q88933659 |
| Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research | Q24289435 | ||
| Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 | ||
| Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease | Q24612662 | ||
| The amyloid hypothesis of Alzheimer's disease at 25 years | Q26749528 | ||
| Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology | Q26774743 | ||
| Plasma biomarkers of brain atrophy in Alzheimer's disease | Q28741028 | ||
| Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease | Q28748461 | ||
| The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29547554 | ||
| The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29614406 | ||
| Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease | Q29614881 | ||
| Clinical and biomarker changes in dominantly inherited Alzheimer's disease | Q29619940 | ||
| The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology | Q29994562 | ||
| Blood-based biomarkers of Alzheimer's disease: challenging but feasible | Q33824444 | ||
| The future of blood-based biomarkers for Alzheimer's disease | Q34026317 | ||
| Errors in laboratory medicine. | Q34125689 | ||
| Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease | Q34141675 | ||
| Plasma clusterin and the risk of Alzheimer disease | Q34176049 | ||
| A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study | Q34341870 | ||
| Developing novel blood-based biomarkers for Alzheimer's disease | Q34394080 | ||
| Plasma based markers of [11C] PiB-PET brain amyloid burden | Q34427001 | ||
| Plasma proteins predict conversion to dementia from prodromal disease | Q34556953 | ||
| Proteome-based plasma biomarkers for Alzheimer's disease | Q34577503 | ||
| A serum protein-based algorithm for the detection of Alzheimer disease | Q34755504 | ||
| Inflammatory proteins in plasma are associated with severity of Alzheimer's disease | Q34769550 | ||
| Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease | Q35028860 | ||
| Peril beyond the winner's curse: A small sample size is the bane of biomarker discovery | Q47240642 | ||
| Blood-based protein biomarkers for diagnosis of Alzheimer disease | Q47378944 | ||
| Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease | Q48155798 | ||
| Analysis of serum β-amyloid peptides, α2-macroglobulin, complement factor H, and clusterin levels in APP/PS1 transgenic mice during progression of Alzheimer's disease. | Q48562021 | ||
| Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly. | Q50221800 | ||
| Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease. | Q50553594 | ||
| Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease. | Q50563223 | ||
| Plasma Complement factor H in Alzheimer's Disease. | Q50601474 | ||
| Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. | Q50646784 | ||
| Prognostic polypeptide blood plasma biomarkers of Alzheimer's disease progression. | Q51162952 | ||
| Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. | Q53305742 | ||
| Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. | Q54996405 | ||
| Mistakes in a stat laboratory: types and frequency | Q73615765 | ||
| The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone | Q82183404 | ||
| Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease | Q35034130 | ||
| Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer's disease | Q35034769 | ||
| Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals | Q35076119 | ||
| Incidence of post-dural puncture headache in research volunteers | Q35552718 | ||
| Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment | Q36182245 | ||
| Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study | Q36316280 | ||
| Alzheimer's disease biomarker discovery using in silico literature mining and clinical validation | Q36430448 | ||
| Assessing candidate serum biomarkers for Alzheimer's disease: a longitudinal study. | Q36740479 | ||
| Diagnosing Alzheimer's disease--non-clinicians and computerised algorithms together are as accurate as the best clinical practice | Q36832420 | ||
| Blood protein predictors of brain amyloid for enrichment in clinical trials? | Q36926754 | ||
| Alzheimer's disease: are blood and brain markers related? A systematic review | Q36966044 | ||
| Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology | Q37044150 | ||
| Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals | Q37100094 | ||
| Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins | Q37347834 | ||
| Plasma protein profiling of Mild Cognitive Impairment and Alzheimer's disease using iTRAQ quantitative proteomics | Q37504001 | ||
| Prospective associations of plasma phospholipids and mild cognitive impairment/dementia among African Americans in the ARIC Neurocognitive Study | Q37543795 | ||
| Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. | Q37617521 | ||
| Progress update: fluid and imaging biomarkers in Alzheimer's disease | Q37626382 | ||
| Plasma phospholipids identify antecedent memory impairment in older adults. | Q37714213 | ||
| Autoantibodies for cancer detection: Still cause for excitement? | Q37799474 | ||
| Blood and plasma-based proteomic biomarker research in Alzheimer's disease | Q38022421 | ||
| Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study | Q38152257 | ||
| Blood-based biomarkers of Alzheimer's disease: diagnostic algorithms and new technologies | Q38633281 | ||
| CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis | Q38805517 | ||
| Metabolic network failures in Alzheimer's disease: A biochemical road map. | Q38877855 | ||
| Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress | Q38980003 | ||
| Association of blood lipids with Alzheimer's disease: A comprehensive lipidomics analysis | Q39332217 | ||
| Complement Biomarkers as Predictors of Disease Progression in Alzheimer's Disease | Q39447009 | ||
| Glycosylation of Human Plasma Clusterin Yields a Novel Candidate Biomarker of Alzheimer's Disease | Q40407214 | ||
| Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer's Disease | Q40444820 | ||
| Plasma gelsolin and matrix metalloproteinase 3 as potential biomarkers for Alzheimer disease | Q41086639 | ||
| Deletion of Crry, the murine ortholog of the sporadic Alzheimer's disease risk gene CR1, impacts tau phosphorylation and brain CFH. | Q42103651 | ||
| BDNF, TNFα, HSP90, CFH, and IL-10 serum levels in patients with early or late onset Alzheimer's disease or mild cognitive impairment. | Q44592034 | ||
| Plasma transthyretin as a candidate marker for Alzheimer's disease | Q44768899 | ||
| Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins | Q44917427 | ||
| Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease | Q46155330 | ||
| Alpha-2 macroglobulin in Alzheimer's disease: a marker of neuronal injury through the RCAN1 pathway. | Q47201004 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| biomarker | Q864574 | ||
| P304 | page(s) | 1181-1198 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | Journal of Alzheimer's Disease | Q6294755 |
| P1476 | title | A Decade of Blood Biomarkers for Alzheimer's Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication. | |
| P478 | volume | 62 |
| Q91936689 | A Pilot Proof-Of-Principle Analysis Demonstrating Dielectrophoresis (DEP) as a Glioblastoma Biomarker Platform |
| Q90754603 | A systems approach to clinical oncology uses deep phenotyping to deliver personalized care |
| Q59333275 | Advances in Multi-Functional Ligands and the Need for Metal-Related Pharmacology for the Management of Alzheimer Disease |
| Q99710861 | Blood biomarkers indicate that the preclinical stages of Alzheimer's disease present overlapping molecular features |
| Q60950950 | Blood-Derived Plasma Protein Biomarkers for Alzheimer's Disease in Han Chinese |
| Q64108130 | Blood-based molecular biomarkers for Alzheimer's disease |
| Q95836632 | Circulating asymmetric dimethylarginine and cognitive decline: A four-year follow up study of the 1936 Aberdeen Birth Cohort |
| Q90149235 | Dielectric Constant and Conductivity of Blood Plasma: Possible Novel Biomarkers for Alzheimer's Disease |
| Q93178292 | Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay |
| Q64066945 | Extracellular Vesicle as a Source of Alzheimer's Biomarkers: Opportunities and Challenges |
| Q90604684 | Genetic networks in Parkinson's and Alzheimer's disease |
| Q92387684 | Identification of molecular signatures and pathways to identify novel therapeutic targets in Alzheimer's disease: Insights from a systems biomedicine perspective |
| Q92382299 | Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease |
| Q60959798 | Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [F]-Flutemetamol PET Scan Result |
| Q58779295 | Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias |
| Q64243768 | SOMAscan-based proteomic measurements of plasma brain natriuretic peptide are decreased in mild cognitive impairment and in Alzheimer's dementia patients |
Search more.